Advertisement

Ticagrelor and tirofiban in pregnancy and delivery: beyond labels

  • Donatella Argentiero
  • Stefano Savonitto
  • Paola D’Andrea
  • Fortunato IacovelliEmail author
Article
  • 58 Downloads

Abstract

Pregnancy-associated acute myocardial infarction is a rare condition usually occurring during the third trimester of pregnancy, and associated with three-to-four-fold higher mortality compared with rates among non-pregnant women of the same age. As in non-pregnant women, in cases of ST elevation myocardial infarction, the most effective treatment is primary percutaneous coronary intervention with stent implantation. Unfortunately, management of these patients could be challenging because little is known about the optimal medical strategy; the potential teratogenic effects of the third generation thienopyridines are not fully established too. In fact current guidelines do not provide enough recommendations about tailoring dual antiplatelet therapy prescription according to ischemic profile of the pregnant patients. Moreover, the bleeding risk class of cesarean delivery/hysterectomy is not stated in current consensus documents. We report the second pregnancy-associated acute myocardial infarction case successfully treated with ticagrelor before and after primary percutaneous coronary intervention with drug eluting stent implantation on left coronary artery, but also the first report on use of bridging antiplatelet therapy with tirofiban during temporary withdrawal of ticagrelor because of a C-section.

Keywords

Pregnancy Cesarean section Acute myocardial infarction Percutaneous coronary intervention Ticagrelor Tirofiban 

Notes

Acknowledgements

We would like to thank Dr. Vitantonio Russo and Dr. Francesca Pierri, from the Division of Cardiology of the “SS. Annunziata” Hospital of Taranto (Italy), for such off-label effective antiplatelet management of the patient during the admission for ST elevation myocardial infarction and at the time of delivery.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J et al (2018) 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. The task force for the management of cardiovascular diseases during pregnancy of the European society of cardiology (ESC). Eur Heart J 39:3165–3241CrossRefPubMedGoogle Scholar
  2. 2.
    Firoz T, Magee LA (2012) Acute myocardial infarction in the obstetric patient. Obstet Med 5:50–57CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cauldwell M, Baris L, Ross-Hesselink JW, Johnson MR (2018) Ischaemic heart disease and pregnancy. Heart 0:1–7Google Scholar
  4. 4.
    Verbruggen M, Mannaerts D, Muys J, Jacquemyn Y (2015) Use of ticagrelor in human pregnancy, the first experience. BMJ Case Rep.  https://doi.org/10.1136/bcr-2015-212217 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tello-Montoliu A, Seecheran NA, Angiolillo DJ (2013) Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. J Thromb Thrombolysis 36:348–351CrossRefPubMedGoogle Scholar
  6. 6.
  7. 7.
    Ibanez B, James S, Agewall S et al (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 39:119–177CrossRefPubMedGoogle Scholar
  8. 8.
  9. 9.
    Renda G, Patti G, Lang IM (2019) Thrombotic and hemorrhagic burden in women: gender-related issues in the response to antithrombotic therapies. Int J Cardiol 286:198–207CrossRefPubMedGoogle Scholar
  10. 10.
    Lai CH, Lee WL, Sung SH et al (2015) Comparison of bare-metal stent and drug-eluting stent for the treatment of patients undergoing percutaneous coronary intervention for unprotected left main coronary artery disease—long-term result from a single center experience. Acta Cardiol Sin 31:381–389PubMedPubMedCentralGoogle Scholar
  11. 11.
    Rossini R, Musumeci G, Oltrona Visconti L et al (2014) Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention 10:38–46CrossRefPubMedGoogle Scholar
  12. 12.
    Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–254CrossRefPubMedGoogle Scholar
  13. 13.
    Savonitto S, D’Urbano M, Caracciolo M et al (2010) Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104:285–291CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of University Cardiology, Cardiothoracic DepartmentPoliclinico University HospitalBariItaly
  2. 2.Division of Cardiology“A. Manzoni” HospitalLeccoItaly
  3. 3.Department of Pharmacy - Pharmaceutical SciencesUniversity of Bari “Aldo Moro”BariItaly

Personalised recommendations